Medicare pays plans to prevent kidney disease—but will it work?

What it does

This bill directs the Secretary of Health and Human Services to create a 10-year voluntary demonstration program allowing health insurance plans (commercial, Medicaid, Medicare Advantage) to share in Medicare savings they generate by preventing kidney disease progression to end-stage renal disease (ESRD). Plans that meet performance benchmarks and provide comprehensive kidney care services—including screening, FDA-approved drugs, nutrition, and disease management—can receive 25% of the Medicare savings they produce, funded from Medicare trust funds.

Why we flagged it

The bill's core mechanism is a voluntary shared-savings demonstration program that pays health plans a percentage of Medicare savings generated by preventing ESRD progression. It is structured as a public-health intervention (preventing kidney disease) but operates through financial incentives to private and public plans, making it a hybrid public-health/market-based approach.

What the text implies

• Plans may prioritize enrollment of lower-risk kidney disease patients to maximize savings relative to benchmark, potentially leaving higher-risk patients underserved despite anti-avoidance language.
• Advance investment payments (up to the amount of shared savings) create a subsidy mechanism that may exceed actual Medicare savings, shifting costs to taxpayers without guaranteed clinical benefit.
• The program's success depends on plans' voluntary participation; if uptake is low, the $5M annual administrative cost may not generate sufficient savings to justify the program.
• Benchmark-setting methodology (historical rates, regional prevalence, screening adjustments) is discretionary and may be gamed by plans or set too generously, reducing actual Medicare savings.
• The 10-year duration and $5M annual administrative budget suggest a pilot, but shared savings payments are open-ended and could exceed initial projections if many plans participate and exceed benchmarks.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens with kidney disease gain access to comprehensive preventive services (screening, drugs, nutrition, disease management) at reduced cost-sharing, potentially delaying or preventing ESRD and its $50B annual Medicare burden. However, the program's success depends on plans' voluntary participation and actual implementation; the shared savings mechanism may incentivize plans to focus on lower-risk patients, and the program's net fiscal impact on Medicare (and thus taxpayers) is uncertain—savi

Who stands to gain

• Health insurance plans (commercial, Medicaid, Medicare Advantage) receiving 25% of Medicare savings
• Pharmaceutical companies (drugs with kidney-function-preservation indications)
• Healthcare providers and disease management vendors contracted by participating plans

Named in the bill

Secretary of Health and Human Services, Centers for Medicare and Medicaid Services (CMS), Medicare (Parts A, B, D), Medicaid, Medicare Advantage (Part C), Federal Hospital Insurance Trust Fund, Federal Supplementary Medical Insurance Trust Fund, Food and Drug Administration (FDA), Chief Actuary of CMS

Where it stands

• Jul 22, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 22, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.